TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.

ABSTRACT:

Background

The assessment of TP53 mutational status is becoming a routine clinical practice for chronic lymphocytic leukemia patients (CLL). A broad spectrum of molecular techniques has been employed so far, including both direct Sanger sequencing and next generation sequencing. Oxford Nanopore Technologies recently released the MinION an USB-interfaced sequencer. In this paper we report our experience, with the MinION technology for the detection of the TP53 gene mutation in CLL patients. Twelve CLL patients at diagnosis were included in this study. All except one patient showed the TP53 gene deletion in Fluorescence in situ hybridization experiments. Patients were investigated for TP53 mutation by Sanger and by MinION sequencing. Analysis by Sanger was performed according with th

SUBMITTER: Minervini CF 

PROVIDER: S-EPMC5057401 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature